What the evidence actually says
GLP-1 and peptide research: approvals, trial findings and costs, with links to labels, trials and FDA records.
Showing 67 of 67 articles
- Peptide evidenceCJC-1295 and ipamorelin: what the blend is
- Price and evidenceFoundayo (orforglipron): price and how to get it
- ComparisonHims vs Hers vs Ro for weight loss
- Price and evidenceNAD+ injections at home: cost and evidence
- ComparisonNoom Med vs WeightWatchers Clinic for GLP-1s
- Price and evidenceSermorelin online: cost and side effects
- Price and evidenceWegovy pill vs injection: weight loss, side effects and monthly cost
- Trial evidenceGLP-1s and heart disease: the trial that changed what these drugs are for
- Label evidenceGLP-1s before surgery: the label warning your telehealth form never asks about
- Trial evidenceGLP-1s for sleep apnea: the indication that survives when weight loss does not
- Label evidenceHair loss is on both labels, and the number is almost entirely a women's number
- Product evidenceOral GLP-1s: two approved weight-loss pills, and no oral tirzepatide
- Pipeline evidenceRetatrutide and the next GLP-1s: trials, approvals and prices
- Prescribing mechanicsTestosterone by telehealth: the one prescription running on a deadline
- Label evidenceThe birth-control interaction that only one of these drugs has
- Label evidenceThe boxed warning is about rats, and the human studies disagree with each other
- Trial evidenceTirzepatide vs semaglutide: the one trial that put them in the same room
- Peptide safetyBPC-157 side effects: what small human studies can show
- Buyer guideBrand versus compounded, on price: the spread is not what you were told
- Peptide evidenceCJC-1295: two early trials and limited clinical evidence
- GLP-1 evidenceGLP-1 side effects, by how often the trials reported them
- GLP-1 evidenceGLP-1s and alcohol: three randomized trials, and what each one moved
- Compounded supplyImpurities in compounded GLP-1s: what has actually been measured
- Peptide evidenceIpamorelin: two trials, and the one that mattered missed
- Peptide safetyIV glutathione: the same failure, seven years apart
- GLP-1 evidenceLean mass on a GLP-1: what the trials that measured it found
- Compounded supplyMilligrams, milliliters, units: how a compounded vial gets mismeasured
- GLP-1 evidenceNausea on a GLP-1: what has actually been tested against it
- Compounded supplyOut of the fridge: storage and beyond-use dating on a compounded GLP-1
- Access guidePrior authorization for a GLP-1, and what a denial actually turns on
- Buyer guideSemaglutide with B12: the claims, and what was measured
- GLP-1 evidenceStopping a GLP-1: what happened in the trials that stopped it on purpose
- Buyer guideSwitching GLP-1 providers: what transfers, what is forfeited, and what starts over
- Peptide evidenceTB-500: the trials belong to a different molecule
- Peptide evidenceTesamorelin is an approved drug, and the label rules out the reason it is sold
- Buyer guideWhat a GLP-1 costs in cash, and why nobody can name the cheapest
- Buyer guideWhat the dose ladder costs: the brand market prices milligrams, the compounded market prices months
- Compounded supplyWhere compounded semaglutide stands with the FDA, with the dates
- Add-on evidenceB12 and lipotropic shots: what the injection is approved to do
- Peptide evidenceBPC-157: what the FDA actually said, and what the trials show
- Buyer guideCompounded semaglutide with B12: what adding the vitamin changes
- ReferenceEvery peptide on a telehealth menu, and where the FDA actually put it
- Peptide evidenceIV glutathione: the FDA is investigating, and dermatology already ruled
- Add-on evidenceLow-dose naltrexone: what the trials found when they got bigger
- Add-on evidenceMethylene blue: an emergency IV drug sold as a daily supplement
- Buyer guideMicrodosing a GLP-1: what the evidence search found
- Peptide evidenceNAD+ drips: one randomized trial, and it wasn't about energy
- Peptide evidencePT-141: what was approved, and who it was approved for
- Peptide evidenceSermorelin: the peptide that used to be an approved drug
- ExplainerAre peptides legal? BPC-157, TB-500 and the July 2026 FDA panel vote
- Buyer guideCompounded tirzepatide in 2026: legal status and cost
- Compounded supplyFDA warning letters to telehealth sellers in 2026
- FDA and priceGeneric semaglutide: what tentative approval means
- Compounded supplyTirzepatide units to mg: a vial conversion chart
- Price guideTrumpRx GLP-1 prices and how to use them
- Price guideWegovy cost without insurance: pen, pill and HD
- Price guideZepbound cost without insurance, by dose and form
- Buyer guideHow to verify a compounding pharmacy, and what the FDA register will not tell you
- Access guideState Medicaid and GLP-1s: the same federal permission, forty-two different answers
- Access guidePaying for a GLP-1 with HSA or FSA money: what the IRS publications actually say
- Buyer guideThe subscription mechanics: renewal cycles, prepaid terms, and the charge that beats the calendar
- Buyer guideWhat “third-party tested” proves, and what it doesn’t
- Buyer guideWhat happens to your money: seven telehealth refund policies, read in full
- Buyer guideCompounded versus brand GLP-1s, without the marketing
- Buyer guideHow a telehealth prescription actually happens
- Buyer guideWhat “starting at” is really buying you
- Buyer guideWhat a telehealth membership actually buys
Educational content, not medical advice. Talk to a licensed clinician before starting any treatment. How we judge a company is separate: see how we grade, how we verify prices and our provider reviews.